Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Change in Accured Expenses (2020 - 2025)

Cytek Biosciences' Change in Accured Expenses history spans 6 years, with the latest figure at $4.7 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 60.28% year-over-year to $4.7 million; the TTM value through Dec 2025 reached $4.0 million, up 585.92%, while the annual FY2025 figure was $4.0 million, 585.92% up from the prior year.
  • Change in Accured Expenses reached $4.7 million in Q4 2025 per CTKB's latest filing, up from -$1.4 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $8.9 million in Q4 2021 to a low of -$4.8 million in Q2 2024.
  • Average Change in Accured Expenses over 5 years is $1.1 million, with a median of $462500.0 recorded in 2021.
  • The largest YoY upside for Change in Accured Expenses was 2368.91% in 2024 against a maximum downside of 360.86% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $8.9 million in 2021, then crashed by 47.72% to $4.6 million in 2022, then crashed by 97.44% to $119000.0 in 2023, then soared by 2368.91% to $2.9 million in 2024, then skyrocketed by 60.28% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Change in Accured Expenses are $4.7 million (Q4 2025), -$1.4 million (Q3 2025), and $2.8 million (Q2 2025).